Search | OpenScholar

Search results

374 results found

News

Page

Kelly Hussey, MPAS, PA-C

Person: Sub-Investigator, Physician Assistant

Kelly graduated with a Master’s degree in Physician Assistant Studies from the University Of Florida College Of Medicine. She is excited to be a member of the team at the USF Parkinson’s Disease and Movement Disorders Center. She has been working with Dr. Hauser at USF since 2012 and is the sub...

Evelyn Spiller, BS

Person: Clinical Research Associate, Study Coordinator

Evelyn Spiller holds a Bachelor of Science degree in Public Health and Infectious Disease. She has amassed two and a half years of research experience, encompassing trials in Infectious Disease, General Surgery, and a year and a half focused on Neurology. Currently, she coordinates four Randomized...

for the P2B Study Group. Double-Blind Study comparing P2B001 (combination of low-doses of extended-release Pramipexole and Rasagiline) to components and to optimised doses of Pramipexole-extended release in early Parkinson’s Disease.

Publication: Journal Article

Hauser, RA, CW Olanow, D Burdick, R Dhall, JA de Marcaida, RA Gil, DL Kreitzman, L Elmer, A McGarry, and K Kieburtz. 2024. “For the P2B Study Group. Double-Blind Study Comparing P2B001 (combination of Low-Doses of Extended-Release Pramipexole and Rasagiline) to Components and to Optimised Doses of Pramipexole-Extended Release in Early Parkinson’s Disease.”. . Mov Disord. 2024 Feb;39(2):350-359. Doi: 10.1002/Mds.29642. Epub 2023 Oct 27. PMID: 37886872.

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.

Publication: Journal Article

Fung, VSC, J Aldred, MP Arroyo, F Bergquist, RA Hauser, M Bouchard, S Bray, et al. 2024. “Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion for the Treatment of Motor Fluctuations in Parkinson’s Disease: Considerations for Initiation and Maintenance.”. . Clin Park Relat Disord. 2024 Feb 10;10:100239. Doi: 10.1016/J.prdoa.2024.100239. ECollection 2024. PMID: 38419617.

OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.

Publication: Journal Article

Hauser, RA, A Videnovic, P Soares-da-Silva, GS Liang, K Olson, E Jen, JF Rocha, and O Klepitskaya. 2024. “OFF-Times Before, During, and After Nighttime Sleep Periods in Parkinson’s Disease Patients With Motor Fluctuations and the Effects of Opicapone: A Post Hoc Analysis of Diary Data from BIPARK-1 and -2.”. Parkinsonism Relat Disord. 2024 Jun;123:106971. Doi: 10.1016/J.Parkreldis.2024.106971. Epub 2024 Apr 9.PMID: 38631081 .

Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. doi: 10.1002/mds.29392. Epub 2023 Apr 20. PMID: 37081740

Publication: Journal Article

Martino, D, V Karnik, R Bhidayasiri, DA Hall, RA Hauser, A Macerollo, TM Pringheim, et al. 2023. “Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. Doi: 10.1002/Mds.29392. Epub 2023 Apr 20. PMID: 37081740”. Mov Disord.

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. doi: 10.1007/s40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.

Publication: Journal Article

Hauser, RA, A Favit, LA Hewitt, A Lindsten, S Gomy, S Kymes, and SH Isaacson. 2022. “Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. Doi: 10.1007/S40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.”. Neurol Ther.

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.

Publication: Journal Article

Hauser, RA, N Giladi, W Poewe, J Brotchie, H Friedman, S Oren, and P Litman. 2022. “P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Adv Ther. 2022 May;39(5):1881-1894. Doi: 10.1007/S12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.”. Adv. Ther.

Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. doi: 10.3389/fneur.2022.773999. eCollection 2022. PMID: 35280262.

Publication: Journal Article

Hauser, RA, H Barkway, HH Fernandez, SA Factor, J Jimenez-Shahed, N Gross, L Marinelli, et al. 2022. “Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. Doi: 10.3389/Fneur.2022.773999. ECollection 2022. PMID: 35280262.”. Front Neurol.